IRONWOOD PHARMACEUTICALS INC - 10-Q Filing
Ironwood Pharmaceuticals filed a 10-Q for the quarter ended March 31, 2026, disclosing financial results and operational updates. The filing includes details on collaborative arrangements, including royalty revenue from AbbVie related to Linzess in North America and Europe, and a reduction in workforce in January 2025. The company also provided updates on its secured revolving credit facility and convertible notes due in 2026.
Tickers: $IRWD